Alumni Ventures Group
Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Wisconsin
Kalderos
Venture Round in 2022
Kalderos, Inc. is a healthcare technology company that specializes in drug discount management solutions. Founded in 2016 and headquartered in Chicago, Illinois, with an additional location in Brookfield, Wisconsin, Kalderos offers a software-as-a-service (SaaS) platform designed to analyze and optimize the coordination of drug discount programs for healthcare providers, manufacturers, and payers. The platform employs advanced models and machine learning processes to identify and resolve non-compliance issues, detect inconsistencies, and provide data management capabilities. By offering features such as claims verification, dispute resolution, and discount monitoring, Kalderos enables its clients to streamline the communication and payment processes associated with drug discounts, ultimately eliminating waste and enhancing efficiency in the healthcare system.
Lumanu
Series A in 2021
Founded in 2016, Lumanu develops a digital platform connecting companies with brand ambassadors. It offers solutions like SocialCert for influencer content sharing, Content Manager for ingesting content, and SmartBoost for creating ads using influencer creatives. Serving brand marketers, performance marketers, agency marketers, and creators/influencers, Lumanu operates from Oakland, California with an additional office in Milwaukee, Wisconsin.
Asto CT
Series B in 2021
Asto CT is a veterinary imaging company that develops X-ray computed tomography systems for horses, enabling safe, weight-bearing 3D imaging to diagnose and monitor conditions such as lameness, distal limb disease, fractures, and tooth or sinus problems. Its Equina solution provides rapid 3D scans of the lower limbs, head, and neck in standing horses without general anesthesia, supporting early detection and improved treatment planning for Thoroughbreds, other sport and recreation horses, and older animals. The company emphasizes high-quality imaging, ease of use, and integration of advanced robotics with fan-beam CT technology to enhance diagnostic capability and veterinary care. Founded in 2015 and based in Madison, Wisconsin, Asto CT aims to improve horse welfare by enabling safer, more accurate assessment while minimizing anesthesia risks.
SHINE
Series C in 2021
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
Cultured Decadence
Seed Round in 2020
Cultured Decadence is a cellular aquaculture startup based in Madison, Wisconsin, founded in 2020. The company specializes in innovative methods to produce crustacean products, specifically focusing on lobster and crab meat. Utilizing cell culture and tissue engineering techniques, Cultured Decadence creates seafood directly from the cells of these animals, eliminating the need for shells, organs, and waste. This approach aims to address the increasing global demand for nutritious and sustainable seafood, providing a more environmentally friendly alternative to traditional fishing practices.
SHINE
Venture Round in 2020
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
Asto CT
Venture Round in 2019
Asto CT is a veterinary imaging company that develops X-ray computed tomography systems for horses, enabling safe, weight-bearing 3D imaging to diagnose and monitor conditions such as lameness, distal limb disease, fractures, and tooth or sinus problems. Its Equina solution provides rapid 3D scans of the lower limbs, head, and neck in standing horses without general anesthesia, supporting early detection and improved treatment planning for Thoroughbreds, other sport and recreation horses, and older animals. The company emphasizes high-quality imaging, ease of use, and integration of advanced robotics with fan-beam CT technology to enhance diagnostic capability and veterinary care. Founded in 2015 and based in Madison, Wisconsin, Asto CT aims to improve horse welfare by enabling safer, more accurate assessment while minimizing anesthesia risks.
Somna Therapeutics
Venture Round in 2018
Somna Therapeutics LLC, founded in March 2012 in partnership with the Medical College of Wisconsin, is a medical device company based in Germantown, Wisconsin. The company specializes in developing solutions for laryngopharyngeal reflux (LPR) and extraesophageal acid reflux diseases (EERD). Its primary product, the Reza Band, is a non-pharmacologic, investigational device designed to prevent reflux into the larynx, pharynx, and lungs. This non-invasive device aims to improve the quality of life for individuals suffering from these conditions. Somna Therapeutics is currently focused on optimizing product design and completing clinical trials to obtain FDA clearance, with plans to market the Reza Band to hospitals, physician clinics, and home health care providers upon successful approval and launch.
HealthMyne
Series B in 2018
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, specializing in innovative search, analytics, and imaging solutions tailored for cancer care providers. Founded in 2013, the company aims to enhance clinical decision-making by offering real-time, evidence-based imaging insights that support optimized patient care and reduce delivery costs. HealthMyne's technology enables physicians to manipulate tumor images and access electronic health records and image repositories, facilitating the diagnosis and treatment of similar cases. The company’s platform also focuses on improving patient management through features such as automatic tumor staging, dose overlays, and specialized reporting, which streamline clinical workflows and support precision medicine initiatives.
Farcast
Series C in 2018
Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.
SHINE
Series B in 2018
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
HealthMyne
Venture Round in 2017
HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, specializing in innovative search, analytics, and imaging solutions tailored for cancer care providers. Founded in 2013, the company aims to enhance clinical decision-making by offering real-time, evidence-based imaging insights that support optimized patient care and reduce delivery costs. HealthMyne's technology enables physicians to manipulate tumor images and access electronic health records and image repositories, facilitating the diagnosis and treatment of similar cases. The company’s platform also focuses on improving patient management through features such as automatic tumor staging, dose overlays, and specialized reporting, which streamline clinical workflows and support precision medicine initiatives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.